FDA Accepts Biogen ’s Aducanumab Biologics License Application for Alzheimer ' s Disease with Priority Review

CAMBRIDGE, Mass. and TOKYO, Aug. 07, 2020 (GLOBE NEWSWIRE) -- Biogen (Nasdaq: BIIB) and Eisai, Co., Ltd. (Tokyo, Japan) today announced that the U.S. Food and Drug Administration (FDA) has accepted the Biologics License Application (BLA) for...
Source: Drugs.com - Clinical Trials - Category: Pharmaceuticals Source Type: clinical trials